Eicosapentaenoic acid/metformin

Drug Profile

Eicosapentaenoic acid/metformin

Alternative Names: Eicosapentaenoate/metformin; Metformin/eicosapentaenoate; Metformin/eicosapentaenoic acid; TP-101

Latest Information Update: 22 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Thetis Pharmaceuticals
  • Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Eicosanoids; Omega 3 fatty acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Hypertriglyceridaemia; Type 2 diabetes mellitus

Most Recent Events

  • 22 Mar 2016 No recent reports on development identified - Phase-I for Hypertriglyceridaemia (In volunteers) in USA (PO)
  • 22 Mar 2016 No recent reports on development identified - Phase-I for Type-2 diabetes mellitus (In volunteers) in USA (PO)
  • 31 Mar 2014 Phase-I clinical trials in Hypertriglyceridaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top